ACRUX LTD. Aktie

View in Terminal

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2015, ACRUX LTD. Aktie has already paid €0.0379 in dividends. The last payout was in September 2015.

Financials

In the last quarter, ACRUX LTD. Aktie had revenue of €1.76m and net profit of -€465.73k

(EUR)	June 2026	YoY
Revenue	1.76m	-
Gross profit	1.63m	-
Net profit	-465.73k	-
EBITDA	-382.76k	-

Fundamentals

Metric	Value
Market capitalization	€3.4m
Number of shares	612.15m
52-week high/low	€0.0129 - €0.00555
Dividends	No
Beta	1.02
P/E ratio	-6.43
PEG ratio	-0.03
P/B ratio	2.58
P/S ratio	1.19

Company profile

Acrux Limited, together with its subsidiaries, develops and commercializes generic and topical pharmaceuticals in Australia, Europe, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of adult males who have low or no testosterone. It also provides estradiol sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause. The company was incorporated in 1998 and is based in West Melbourne, Australia.